Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
The Oncologist
|
April 15, 2006
Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia
Ralph Boccia, Imtiaz A Malik, Vinay Raja, et al.
The Journal of Supportive Oncology
|
April 6, 2011
Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial)
James R Berenson, Ralph Boccia, Timothy Lopez, et al.
Breast Cancer Research and Treatment
|
September 28, 2005
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients
Claudine Isaacs, Rebecca Slack, Edmund Gehan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 2004
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)
Ralph Boccia, Pramila Rani Anné, Jean Bourhis, et al.
Leukemia Research
|
June 24, 2019
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Parameswaran Hari, Claudia E Paba-Prada, Peter M Voorhees, et al.
Blood
|
November 28, 2018
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Meletios Dimopoulos, David Siegel, Darrell J White, et al.
Leukemia
|
May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)
Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
The New England Journal of Medicine
|
November 12, 2010
Romiplostim or standard of care in patients with immune thrombocytopenia
David J Kuter, Mathias Rummel, Ralph Boccia, et al.
British Journal of Haematology
|
January 13, 2021
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia
Ralph Boccia, Nichola Cooper, Waleed Ghanima, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
Matti Aapro, Ralph Boccia, Robert Leonard, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
The Oncologist
|
April 15, 2006
Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia
Ralph Boccia, Imtiaz A Malik, Vinay Raja, et al.
The Journal of Supportive Oncology
|
April 6, 2011
Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial)
James R Berenson, Ralph Boccia, Timothy Lopez, et al.
Breast Cancer Research and Treatment
|
September 28, 2005
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients
Claudine Isaacs, Rebecca Slack, Edmund Gehan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 2004
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)
Ralph Boccia, Pramila Rani Anné, Jean Bourhis, et al.
Leukemia Research
|
June 24, 2019
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Parameswaran Hari, Claudia E Paba-Prada, Peter M Voorhees, et al.
Blood
|
November 28, 2018
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Meletios Dimopoulos, David Siegel, Darrell J White, et al.
Leukemia
|
May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)
Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
The New England Journal of Medicine
|
November 12, 2010
Romiplostim or standard of care in patients with immune thrombocytopenia
David J Kuter, Mathias Rummel, Ralph Boccia, et al.
British Journal of Haematology
|
January 13, 2021
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia
Ralph Boccia, Nichola Cooper, Waleed Ghanima, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
Matti Aapro, Ralph Boccia, Robert Leonard, et al.
Page
of 5